Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing
Our results indicated higher annual direct costs per patient treated with SCIg than IVIg, despite higher in-hospital costs associated with IVIg administration. Further research, including understanding costs to patients, is warranted.
Authors
- Kylie Rushford
- Allison Mo (ORCID: https://orcid.org/0000-0002-1923-3133)
- Sara Carrillo de Albornoz (ORCID: https://orcid.org/0000-0002-1206-5392)
- Jessica Guglielmino
- Angelene Jesurajah
- Alisa M. Higgins (ORCID: https://orcid.org/0000-0001-8295-7559)
- Dennis Petrie (ORCID: https://orcid.org/0000-0002-3882-2531)
- Terri Dunstan
- Erin Hu (ORCID: https://orcid.org/0009-0004-8806-9105)
- Helen E Haysom
- E. C. Wood (ORCID: https://orcid.org/0009-0002-2894-9050)
- Dan Andrew
- Karinna Saxby
- Philomina Banahene
- Amanda Ellison
- Zoe K. McQuilten
- Loo Sin Hoo
Institutions
- The University of Melbourne (AU)
- Monash Medical Centre (AU)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s00520-026-10551-y
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00